AU2018230737B2 - Tyk2 inhibitors, uses, and methods for production thereof - Google Patents

Tyk2 inhibitors, uses, and methods for production thereof Download PDF

Info

Publication number
AU2018230737B2
AU2018230737B2 AU2018230737A AU2018230737A AU2018230737B2 AU 2018230737 B2 AU2018230737 B2 AU 2018230737B2 AU 2018230737 A AU2018230737 A AU 2018230737A AU 2018230737 A AU2018230737 A AU 2018230737A AU 2018230737 B2 AU2018230737 B2 AU 2018230737B2
Authority
AU
Australia
Prior art keywords
compound
disorder
compounds
disease
tyk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018230737A
Other languages
English (en)
Other versions
AU2018230737A1 (en
Inventor
Jean-Baptiste ARLIN
Jeremy Robert Greenwood
Jon P. Lawson
Jonathan James LOUGHREY
Craig E. Masse
David Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2018230737A1 publication Critical patent/AU2018230737A1/en
Application granted granted Critical
Publication of AU2018230737B2 publication Critical patent/AU2018230737B2/en
Priority to AU2022256121A priority Critical patent/AU2022256121A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: NIMBUS LAKSHMI, INC.
Priority to AU2024205575A priority patent/AU2024205575A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018230737A 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof Active AU2018230737B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022256121A AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468688P 2017-03-08 2017-03-08
US62/468,688 2017-03-08
PCT/US2018/021265 WO2018165240A1 (en) 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022256121A Division AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof

Publications (2)

Publication Number Publication Date
AU2018230737A1 AU2018230737A1 (en) 2019-09-19
AU2018230737B2 true AU2018230737B2 (en) 2022-09-22

Family

ID=63446346

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018230737A Active AU2018230737B2 (en) 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof
AU2022256121A Abandoned AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A Pending AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022256121A Abandoned AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A Pending AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Country Status (10)

Country Link
US (2) US10336752B2 (https=)
EP (2) EP4338802A3 (https=)
JP (3) JP7160824B2 (https=)
CN (1) CN110582501B (https=)
AR (1) AR111233A1 (https=)
AU (3) AU2018230737B2 (https=)
CA (1) CA3055209A1 (https=)
IL (1) IL269036B2 (https=)
TW (3) TWI783978B (https=)
WO (1) WO2018165240A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
AU2019234574A1 (en) 2018-03-12 2020-09-03 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
US20220135567A1 (en) * 2019-02-07 2022-05-05 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
AU2020247990A1 (en) 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
IL311624A (en) * 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
CN118974052A (zh) * 2022-03-25 2024-11-15 武田药品工业株式会社 Tyk2抑制剂的固体形式和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4983612A (en) * 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4343923A1 (de) * 1993-12-22 1995-06-29 Basf Ag Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
WO2004046103A2 (en) * 2002-11-18 2004-06-03 The Regents Of The University Of California Arylpyridine compounds
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2620376C2 (ru) * 2010-12-22 2017-05-25 Людвиг-Максимилианс-Университэт Мюнхен Цинкорганические комплексы, способы их получения и применение
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
DK2634185T3 (en) * 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
EP2855451B1 (en) * 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3262049B1 (en) * 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brittain, H.G. in "Polymorphism in Pharmaceutical Solids", (1999), Marcel Dekker, Inc., New York, Edited by Brittain. *

Also Published As

Publication number Publication date
TW202321243A (zh) 2023-06-01
JP2020511438A (ja) 2020-04-16
US10336752B2 (en) 2019-07-02
JP7535086B2 (ja) 2024-08-15
AU2018230737A1 (en) 2019-09-19
US20190337941A1 (en) 2019-11-07
IL269036A (en) 2019-10-31
IL269036B2 (en) 2023-03-01
EP3592746A1 (en) 2020-01-15
TWI868528B (zh) 2025-01-01
EP3592746B1 (en) 2024-01-24
JP2024153877A (ja) 2024-10-29
JP7160824B2 (ja) 2022-10-25
EP4338802A3 (en) 2024-09-04
JP2022185139A (ja) 2022-12-13
WO2018165240A1 (en) 2018-09-13
US11040967B2 (en) 2021-06-22
AU2024205575A1 (en) 2024-08-22
AU2022256121A1 (en) 2022-11-17
EP4338802A2 (en) 2024-03-20
TWI783978B (zh) 2022-11-21
CA3055209A1 (en) 2018-09-13
AR111233A1 (es) 2019-06-19
EP3592746A4 (en) 2020-11-25
CN110582501A (zh) 2019-12-17
US20180258086A1 (en) 2018-09-13
TW202515876A (zh) 2025-04-16
CN110582501B (zh) 2022-09-23
TW201840559A (zh) 2018-11-16
IL269036B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
JP7535086B2 (ja) Ｔｙｋ２阻害剤、使用およびその製造のための方法
US10968236B2 (en) TYK2 inhibitors and uses thereof
US9085586B2 (en) IRAK inhibitors and uses thereof
US12338242B2 (en) TYK2 inhibitors and uses thereof
JP2025510844A (ja) Ｔｙｋ２阻害剤の合成及びその中間体
HK40017086B (en) Tyk2 inhibitors, uses, and methods for production thereof
HK40017086A (en) Tyk2 inhibitors, uses, and methods for production thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): NIMBUS LAKSHMI, INC.